Matrix metalloproteinases (MMPs) are zinc‐dependent endopeptidases that were first
discovered as proteases, which target and cleave extracellular proteins. During the past 20 …

Despite many years of research, no biomarkers for stroke are available to use in clinical
practice. Progress in high-throughput technologies has provided new opportunities to …

Hemorrhagic transformation (HT) is a common complication of ischemic stroke that is
exacerbated by thrombolytic therapy. Methods to better prevent, predict, and treat HT are …

Ischemic stroke continues to be one of the most challenging diseases in translational
neurology. Tissue plasminogen activator (tPA) remains the only approved treatment for …

The blood-brain barrier (BBB) is a vital component of the neurovascular unit (NVU)
containing tight junctional (TJ) proteins and different ion and nutrient transporters which …

Inflammation is a classical host defence response to infection and injury that has many
beneficial effects. However, inappropriate (in time, place and magnitude) inflammation is …

Ischemic stroke (IS) is a multifactorial and heterogeneous neurological disorder with high
rate of death and long-term impairment. Despite years of studies, there are still no stroke …

In Alzheimer's disease (AD), the contribution of pathophysiological mechanisms other than
amyloidosis and tauopathy is now widely recognized, although not clearly quantifiable by …

Alzheimer's disease (AD) and vascular dementia (VaD) are intertwined by mixed dementia
(MD) harboring varying degrees of AD pathology in combination with cerebrovascular …

Blood-brain barrier (BBB) disruption is a serious pathological consequence of traumatic
brain injury (TBI), for which there are limited therapeutic strategies. Tissue inhibitor of …